🇺🇸 BNT162b1 in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 7
Most-reported reactions
- Overdose — 2 reports (28.57%)
- Acute Respiratory Failure — 1 report (14.29%)
- Cardiac Arrest — 1 report (14.29%)
- Hypokalaemia — 1 report (14.29%)
- Suicide Attempt — 1 report (14.29%)
- Syncope — 1 report (14.29%)
Other Infectious Disease approved in United States
Frequently asked questions
Is BNT162b1 approved in United States?
BNT162b1 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for BNT162b1 in United States?
BioNTech SE is the originator. The local marketing authorisation holder may differ — check the official source linked above.